RxDoctor Payments Data

Nicolai Mejevoi, MD

Interventional Cardiology · Port Charlotte, FLNPI 1427369131

Payments from drug & device makers

$15,672in general payments, 2019–2025

Across 482 payments — averaging $32.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$4K
  • W. L. Gore & Associates, Inc.$2K
  • Edwards Lifesciences$1K
  • Endologix LLC$877
  • Boston Scientific$753
  • Novartis$683
  • plus $7K from 43 others

What the payments were for

  • Travel & lodging$1,88312%
  • Food & beverage$13,59087%
  • Education$1991%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,672 in reported general payments places this provider in the 60th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$796,042
Medicare patients
984
Services billed
8,678

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban544$648,528
Repatha SureclickEvolocumab438$341,744
XareltoRivaroxaban151$199,373
EntrestoSacubitril/Valsartan172$196,829
FarxigaDapagliflozin Propanediol145$154,093
JardianceEmpagliflozin46$53,298
VascepaIcosapent Ethyl64$42,718
BrilintaTicagrelor40$31,940
MultaqDronedarone Hcl12$23,724
Praluent PenAlirocumab38$23,235
Metoprolol Succinate1,040$12,497
OzempicSemaglutide12$11,453
Ezetimibe476$9,060
DapagliflozinDapagliflozin Propanediol12$7,855
Icosapent Ethyl21$7,064

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$278$648,528544 claims
Johnson & JohnsonXarelto$300$199,373151 claims
NovartisEntresto$683$196,829172 claims
AstraZenecaFarxiga, Brilinta$351$186,033185 claims
Boehringer IngelheimJardiance$343$53,29846 claims
Sanofi-aventis U.S. LLCMultaq$176$23,72412 claims
Novo NordiskOzempic$83$11,45312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Port Charlotte

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →